Leisa Johnson

Title: Leisa Johnson: Innovator in Cancer Treatment

Introduction

Leisa Johnson is a prominent inventor based in South San Francisco, CA (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of phosphoinositide 3-kinase (PI3K) inhibitor compounds. With a total of 2 patents, her work focuses on advancing therapeutic methods for hyperproliferative disorders.

Latest Patents

Leisa Johnson's latest patents include groundbreaking formulations that combine PI3K inhibitor compounds with chemotherapeutic agents. These combinations are designed to treat hyperproliferative disorders such as cancer. The patents detail methods for using these combinations in various settings, including in vitro, in situ, and in vivo, to diagnose, prevent, or treat associated pathological conditions in mammalian cells.

Career Highlights

Throughout her career, Leisa has worked with leading companies in the pharmaceutical industry, including Genentech, Inc. and F. Hoffmann-La Roche AG. Her experience in these organizations has allowed her to collaborate with some of the brightest minds in the field, further enhancing her contributions to cancer research.

Collaborations

Leisa has had the opportunity to work alongside talented colleagues such as Marcia Belvin and Lori Friedman. These collaborations have played a crucial role in the development of her innovative approaches to cancer treatment.

Conclusion

Leisa Johnson's work exemplifies the impact of innovation in the medical field, particularly in the fight against cancer. Her patents and collaborations highlight her dedication to improving therapeutic options for patients.